European Journal of Heart Failure最新文献

{"title":"Withdrawal of medical therapy for heart failure after rhythm control in arrhythmia-induced cardiomyopathy—a call for caution","authors":"Nicolas Girerd, Pardeep Jhund","doi":"10.1002/ejhf.3594","DOIUrl":"10.1002/ejhf.3594","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"27 3","pages":"453-455"},"PeriodicalIF":16.9,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143050865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous risk monitoring and management of heart failure: Rationale and design of the ALLEVIATE-HF trial","authors":"Javed Butler, Rami Kahwash, Muhammad Shahzeb Khan, Bart Gerritse, Aimee Laechelt, Jennifer Wehking, Shantanu Sarkar, Brian van Dorn, Verla Laager, Nirav Patel, Michael R. Zile","doi":"10.1002/ejhf.3595","DOIUrl":"https://doi.org/10.1002/ejhf.3595","url":null,"abstract":"Early identification and management of worsening heart failure (HF) is necessary to prevent disease progression and hospitalizations. The ALLEVIATE-HF (Algorithm Using LINQ Sensors for Evaluation and Treatment of Heart Failure) trial is a prospective, randomized, controlled, double-blind, multicentre trial that aims to assess the safety and efficacy of using the Reveal LINQ™ insertable cardiac monitor (ICM) in patients with HF to continuously monitor and evaluate HF risk status and guide timely interventions.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"45 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143050837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials","authors":"Safia Chatur, Muthiah Vaduganathan, Robert A. Fletcher, Vlado Perkovic, Hiddo Heerspink, Clare Arnott, Carol Pollock, Kenneth W. Mahaffey, Bruce Neal, Meg Jardine, Scott D. Solomon, Brendon L. Neuen","doi":"10.1002/ejhf.3586","DOIUrl":"https://doi.org/10.1002/ejhf.3586","url":null,"abstract":"The sodium–glucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular death and chronic kidney disease (CKD) progression among patients with type 2 diabetes at high cardiovascular risk or with CKD. Patients with type 2 diabetes commonly have coexisting HF or CKD that require treatment with loop diuretics; however, the prognostic implications of oral loop diuretic intensification are not well characterized.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"74 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143020893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hierarchical composite outcomes are here to stay, despite the limitations of the win ratio","authors":"Beth A. Davison, Gad Cotter, Gary G. Koch","doi":"10.1002/ejhf.3590","DOIUrl":"https://doi.org/10.1002/ejhf.3590","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"49 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143020083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of loop diuretics as a marker of risk in clinical trials of heart failure with preserved ejection fraction: Analysis from the Swedish Heart Failure Registry","authors":"Fouad Chouairi, Marat Fudim, Gianluigi Savarese, Barna Szabo, Ulf Dahlström, Camilla Hage, Federica Guidetti, Lina Benson, Lars H. Lund","doi":"10.1002/ejhf.3578","DOIUrl":"https://doi.org/10.1002/ejhf.3578","url":null,"abstract":"It is common in heart failure (HF) trials, especially in HF with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF), to select for increased risk of outcomes (‘enrichment’). We investigated the association between loop diuretic use and common trial outcomes.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"300 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating growth differentiation factor-15 levels are associated with early echocardiographic signs of diastolic function impairment in the STANISLAS cohort: A 20-year follow-up study","authors":"Luca Monzo, Constance Xhaard, João Pedro Ferreira, Guillaume Baudry, Zohra Lamiral, Kevin Duarte, Erwan Bozec, Jean-Marc Boivin, Olivier Huttin, Patrick Rossignol, Faiez Zannad, Nicolas Girerd","doi":"10.1002/ejhf.3576","DOIUrl":"https://doi.org/10.1002/ejhf.3576","url":null,"abstract":"Early identification of healthy subjects prone to develop cardiac dysfunction may be instrumental to prevention strategies. Our study aimed to evaluate whether circulating levels of growth differentiation factor-15 (GDF-15) could predict adverse changes in echocardiographic indexes of cardiac structure and function in an initially healthy populational familial cohort with a long follow-up (STANISLAS cohort).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"66 10 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beta-blockers and heart failure with mildly reduced and preserved ejection fraction. A personalized approach beyond the heart failure syndrome phenotypes is needed","authors":"José Ramón González-Juanatey, Oscar Otero-García, Michael Böhm","doi":"10.1002/ejhf.3588","DOIUrl":"https://doi.org/10.1002/ejhf.3588","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"37 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The DIGIT-HF trial: Key amendments of study design","authors":"Udo Bavendiek, Dominik Berliner, Nele Henrike Thomas, Xiaofei Liu, Johannes Schwab, Andreas Rieth, Lars S. Maier, Sven Schallhorn, Eleonora Angelini, Fabian Rathje, Mircea-Andrei Sandu, Welf Geller, Thomas Gaspar, Rainer Hambrecht, Marija Zdravkovic, Sebastian Philipp, Dragana Kosevic, Georg Nickenig, Daniel Scheiber, Sebastian Winkler, Peter Moritz Becher, Philipp Lurz, Martin Hülsmann, Christoph Schröder, Anika Seltmann, Heiko von der Leyen, Christian Veltmann, Stefan Störk, Michael Böhm, Armin Koch, Johann Bauersachs","doi":"10.1002/ejhf.3575","DOIUrl":"10.1002/ejhf.3575","url":null,"abstract":"<p>DIGIT-HF is a multicentre, randomized, double-blind, placebo-controlled trial designed to investigate the effect of digitoxin versus placebo on the composite primary endpoint of time to all-cause death and hospital admission for worsening heart failure (HFH) (whichever occurs first) in patients with heart failure (HF) and reduced ejection fraction (HFrEF).<span><sup>1</sup></span> The DIGIT-HF trial is conducted in compliance with the German Drug Law (AMG), the German Good Clinical Practice (GCP) ordinance, ICH GCP guidelines, and other applicable ethical and regulatory requirements. The DIGIT-HF trial is registered at EudraCT (2013-005326-38).</p><p>Since recruitment of the first patient in May 2015, seven key protocol amendments have been implemented to specify and clarify its content, particularly to improve the recruitment to reach the required number of primary endpoint events (<i>Figure</i> 1; for details see online supplementary <i>Table</i> <i>S1</i>). Due to the lower than expected recruitment rate, a blinded sample size/trial duration re-estimation was conducted 40 months after beginning of recruitment. It was estimated that the study duration needed to be extended to observe the required number of 734 primary endpoint events. Consequently, the required number of patients was reduced from 2190 to 1653. Following successful application for continued funding, the trial conduct was extended until the end of 2024 with an increased number of recruitment sites.</p><p>The main challenge of the trial was the lower than expected recruitment, which was probably due to the initial overestimation of the number of patients to be recruited per trial site, although the observed pooled event rate for the primary endpoint was similar as assumed in the sample size calculation. Therefore, the number of trial sites was increased from initially 40 to finally 65. This included extension of the trial to motivated investigators in Austria and Serbia.<span><sup>2</sup></span> In addition, several competing clinical trials recruiting HFrEF populations funded by pharmaceutical companies (e.g. DAPA-HF, EMPEROR-Reduced)<span><sup>3, 4</sup></span> started during the DIGIT-HF trial period, which probably impaired recruitment into DIGIT-HF as well.</p><p>The COVID-19 pandemic also affected recruitment because screening/baseline visits intended to be performed in presence could not be scheduled. Furthermore, trial extension to Serbia was strongly delayed by COVID-19 pandemic just after solving all regulatory issues (e.g. digitoxin is not available and approved in Serbia) mandatory for starting the trial at 10 study sites in Serbia, which significantly affected final recruitment numbers. Overall, the COVID-19 pandemic did affect the study conduct by for example, changing the in-person visits to telephone visits, which may have significantly impaired collection of events, in particular HFH events. To explore potential impact of COVID-19 on the study results, COVID-re","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"27 3","pages":"606-608"},"PeriodicalIF":16.9,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.3575","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort","authors":"Mauro Chiarito, Davide Stolfo, Alessandro Villaschi, Samantha Sartori, Luca Baldetti, Carlo Mario Lombardi, Marianna Adamo, Ferdinando Loiacono, Antonio Maria Sammartino, Mauro Riccardi, Daniela Tomasoni, Riccardo Maria Inciardi, Marta Maccallini, Gaia Gasparini, Benedetta Grossi, Stefano Contessi, Daniele Cocianni, Maria Perotto, Giuseppe Barone, Marco Merlo, Alberto Maria Cappelletti, Gianfranco Sinagra, Daniela Pini, Marco Metra, Matteo Pagnesi","doi":"10.1002/ejhf.3585","DOIUrl":"https://doi.org/10.1002/ejhf.3585","url":null,"abstract":"Accurate selection of patients with severe heart failure (HF) who might benefit from advanced therapies is crucial. The present study investigates the performance of the available risk scores aimed at predicting the risk of mortality in patients with severe HF.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"6 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote patient monitoring in heart failure: A comprehensive meta-analysis of effective programme components for hospitalization and mortality reduction","authors":"Ignace L.J. De Lathauwer, Wessel W. Nieuwenhuys, Frederique Hafkamp, Marta Regis, Rutger W.M. Brouwers, Mathias Funk, Hareld M.C. Kemps","doi":"10.1002/ejhf.3568","DOIUrl":"https://doi.org/10.1002/ejhf.3568","url":null,"abstract":"Methods of non-invasive remote patient monitoring (RPM) for heart failure (HF) remain diverse. Understanding factors that influence the effectiveness of RPM on HF-related and all-cause hospitalizations, mortality, and emergency department visits is crucial for developing successful RPM interventions. This meta-analysis aims to synthesize and compare existing literature on RPM components that impact HF-related and all-cause hospitalizations, mortality and emergency department visits in HF patients.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"62 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}